Filing Flows › Fulgent Genetics (FLGT) › Q3 2025
Fulgent Genetics (FLGT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Fulgent Genetics (FLGT) reported revenue of $84.1M for the third quarter 2025 (Q3 2025), +17% from a year earlier and +3% from the quarter before. Operating margin was -18.3%, net loss $6.8M (8.1% of revenue).
Fulgent Genetics, Q3 2025: revenue $84.1M (+17% year over year), operating margin -18.3%, net loss $6.8M, operating cash flow $11.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $84.1M | +3% | +17% |
| Operating profit | −$15.3M | — | — |
| Net earnings | −$6.8M | — | — |
| Operating cash flow | $11.1M | — | — |
| Free cash flow | $5.1M | — | — |
What changed
Revenue was $84.1M in Q3 2025, up 17% year over year and up 3% from the previous quarter. Laboratory Services was the largest line at 100% of revenue. Laboratory Services added $12.2M year over year (up 17%), 99% of the total change.
Gross margin was 42.2%, up 4.9 points from a year earlier. Operating costs exceeded revenue by $15.3M, an operating margin of -18.3%. Operating expenses grew 16% against revenue growth of 17%. The fastest-growing cost line was Sales & marketing (+28%). The quarter ended with a net loss of $6.8M, narrower than the previous quarter's $19.3M loss. Minority interests bore $218K of it: to shareholders the quarter was a loss of $6.6M. Non-operating items added $7.8M, -104% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $11.1M. Non-cash charges added back $6.0M of depreciation and amortization and $9.7M of share-based compensation. Working capital and other items added $2.2M. Capital expenditures of $6.0M left free cash flow of $5.1M.
Questions
What was Fulgent Genetics' revenue in the third quarter 2025?
Fulgent Genetics (FLGT) reported revenue of $84.1M for the third quarter 2025 (Q3 2025), +17% from a year earlier and +3% from the quarter before.
Was Fulgent Genetics profitable in the third quarter 2025?
Operating loss was $15.3M (-18.3% of revenue) and net loss $6.8M.
Source: Fulgent Genetics 10-Q on SEC EDGAR.